Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-706 with tarlatamab and atezolizumab in first-line extensive-stage small cell lung cancer
jRCT2031260601Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of turmetabart adizutecan, tarlatamab and atezolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Objective response rate and Adverse events. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
turmetabart adizutecantarlatamabatezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031260601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260601.